On Wednesday, March 30, Anne Arundel Medical Center is celebrating National Doctor’s Day as a way to say “thank you” to our doctors. At Anne Arundel Medical Center, we are proud to have you as valued members of the medical staff. Thank you for your compassion, dedication and trust, and for all you do for the patients and families in our community. Come to the luncheon on March 30 from 11am to 2pm at AAMC in the Hospital Pavilion South first floor medical staff lounge. View the terrific menu here.
News and Updates
The Geaton and JoAnn DeCesaris Cancer Institute was awarded a three-year, $1.25 million grant for lung cancer prevention and screening from the Bristol Myers Squibb Foundation.
This grant enables us to expand our lung cancer prevention services. These services will focus on high-risk populations in underserved communities in Anne Arundel, Calvert and Prince George’s counties. “While our lung screening and thoracic oncology programs have continued to expand over the past five years, our successes have been more limited among vulnerable, lower-income and minority populations,” says Stephen Cattaneo, MD, director of Thoracic Surgery. “The grant from the Bristol-Myers Squibb Foundation will allow us the opportunity to better reach and inform these at-risk patients in our area and surrounding Maryland counties about the need for lung cancer screening while providing desperately needed education and resources for smoking cessation.”
In February 2016, the Healthy Anne Arundel Coalition released the latest community health needs assessment. Conducted every three years, the report is a joint effort led by the Anne Arundel County Department of Health, AAMC and University of Maryland Baltimore Washington Medical Center. It presents data and key factors affecting the health of county residents. It serves as the foundation for the coalition’s strategic planning. Highlights include cancer and heart disease, the increasing demand for mental health services, the increasing number of prescription opioid-related deaths, and the use of hospital emergency departments as a catch-all for medical and behavioral health issues that can be better addressed in more appropriate care settings. For more information, contact Christine Crabbs, director of community health improvement, at 443-481-5365 or ccrabbs@AAHS.org. Read the community health needs assessment.
AAMC will be the official team hospital and Anne Arundel Medical Group (AAMG) Orthopedic and Sports Medicine Specialists will be the orthopedic surgeons for the Chesapeake Bayhawks.
“We are proud of our Bayhawks team and thrilled to be their partner. We are excited about the opportunity to bring our healthcare expertise in the community, providing education and prevention of health issues and potential sports-related injuries,” said Dan Redziniak, MD, orthopedic surgeon with AAMG Orthopedic and Sports Medicine Specialists and lead AAMC physician for the Bayhawks.
Calling all health experts! Want to position yourself as a thought leader and gain recognition from the public? Starting in May, we’re holding auditions for our next two AAMC docsTalk hosts. These hosts will be the face of docsTalk, AAMC’s dynamic health education show that explores important medical topics in a live interview format. As a host, you’ll have the opportunity to address current health topics, help our community live healthier and be recognized as a credible medical professional. Plus, you’ll have fun doing it! Read the host description and stay tuned for the audition schedule.
Hospitalist James Welker, MD, and the Research Institute are conducting a clinical trial studying the effectiveness of Andexanet Alfa. This drug reverses the effects of some medicines that prevent blood from clotting normally. This medicine could benefit patients who come to the hospital with acute major bleeding that is potentially life threatening. To learn more, contact Kathy Gray, RN, at 443-481-5868 or Kristine Wood, RN, at 443-481-5738.
The AAMC Research Institute is enrolling participants with HER-2 positive metastatic breast cancer in a clinical research trial evaluating Margetuximab, a new investigational medication. Participants enrolled in the SOPHIA clinical trial will receive either Margetuximab or Herceptin in combination with chemotherapy. The study will enroll 530 participants worldwide with advanced HER-2 positive breast cancer who have received prior treatment with Herceptin, Perjeta and/or Kadcyla and received at least one prior line of chemotherapy. For more information, contact Venita Alston Crawford, RN, at 443-481-4393 or Emily Ross, coordinator, at 443-481-4392.
Adrian Park, MD, and Igor Belyansky, MD, along with the surgical research team, are conducting a study. The study evaluates the outcomes for patients who have the Symbotex mesh implant for laparoscopic repair of abdominal hernia. The team will follow the progress of approximately 50 patients for one year as part of this study. For more information, contact Almaz Holmatova, MD, at oholmatova@AAHS.org or 443-481-4943.